In addition, dulaglutide 750 microgram was non-inferior to insulin glargine
[13] [15] Additionally, GLP-1 medications slow gastric emptying, prolonging the time food remains in the stomach and contributing to increased satiety
The dramatic price reductions under the November 2025 MFN deals could also reduce patient abandonment driven by cost concerns
The percent of employers covering GLP-1s for conditions other than diabetes will stagnate as employers try to stabilize their health care costs, while more of those that cover these medications for weight loss will require utilization management, prescriptions from specific providers, participation in a weight management program and higher expectations from vendor partners to deliver sustainable, cost-effective financial models for this class of medications, The Business Group on Health said in a report last August
Quaranta L, et al
A retrospective cohort study (abstract 2579) presented at #ACR24 explores the benefits of GLP-1Ras in reducing the risk of end-stage renal disease (ESRD) for patients with lupus nephritis (LN)